在KRAS突变非小细胞肺癌中,ATR表达作为预后生物标志物
Li Jiang1, Chao Luo1, Peng Zhang1
1Department of Thoracic Surgery, Xinqiao Hospital, Army (Third Military) Medical University, Chongqing, China.
Journal of thoracic disease
|August 14, 2025
概括
作为预后标志物和治疗点,ATR显示出对KRAS突变非小细胞肺癌 (NSCLC) 的承诺. 高ATR表达预示着更糟糕的生存率,并且像AZ20和AZD6738这样的向疗法可能会使患者受益.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- KRAS突变是非小细胞肺癌 (NSCLC) 的关键驱动因素,与糟糕的结果有关.
- 目前的KRAS G12C抑制剂的疗效有限,对其他KRAS变体缺乏治疗方法.
- 对于KRAS突变NSCLC,需要新的治疗策略.
研究的目的:
- 确定KRAS突变NSCLC的新型治疗点.
- 在NSCLC中选与KRAS功能相关的基因.
- 评估已识别的基因的预后和治疗潜力.
主要方法:
- 根据NSCLC的差异表达,KRAS突变型与野生型瘤 (TCGA) 的更高表达以及KRAS突变型细胞系 (CCLE) 的依赖性得分来选择基因.
- 在TCGA和GSE72094队列中评估候选基因的预后价值.
- 进行基因组丰富分析 (GSEA) 和药物敏感性分析.
主要成果:
- 确定了四个与KRAS功能相关的基因,其中ATR表达与整体存活率有显著联系.
- 高ATR表达是两个队列中KRAS突变NSCLC预后更差的独立预测因素.
- GSEA揭示了ATR与癌症途径的关联,药物敏感性分析确定了AZ20和AZD6738作为潜在的治疗方法.
结论:
- ATR作为一个有前途的预后标志物和治疗点为KRAS突变NSCLC.
- 这些发现支持ATR在预测预后和开发向疗法的作用.
- ATR抑制剂可能为KRAS突变NSCLC患者提供新的治疗途径.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
18.1K
11:00Real-Time Quantitative Measurement of Tumor Cell Migration and Invasion Following Synthetic mRNA Transfection
Published on: June 23, 2023
1.2K
相关概念视频
02:38The Ras Gene
6.4K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.4K
02:39lncRNA - Long Non-coding RNAs
8.9K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.9K
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
03:18Non-LTR Retrotransposons
11.9K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.9K